Financials
Financial year 2025
PHARMA 9220 from Hamme (Vl.), company number BE1019772381, closed financial year 2025 with a result of € 214,716 after tax. For that financial year PHARMA 9220 recorded a gross margin of € 320,474 and equity of € 497,987. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 23, 2026.
€ 497,987
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 214,716
Profit after tax over the fiscal year.
€ 458,412
Cash and bank balances on the last day of the fiscal year.
€ 214,716 paid out
100 % of the profit went to the shareholders, mostly to K & G (100 % of the shares). That is where the money ends up.
People and assets in 2025
0.3
Average over the fiscal year, from the social balance sheet.
€ 15,511
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 220
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 173,201
Supplier invoices still open on the last day of the fiscal year.
€ 10,899
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
What happened to PHARMA 9220?
What happened at PHARMA 9220 in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 214,716. Source: NBB ↗
- New establishment in Hamme (Vl.). KBO
- K & G BV became a director. NBB
- Start of the company according to the CBE. KBO
In short
Paid € 34,824 in corporate taxes since 2025.
Paid out € 214,716 in dividends to the owners in total.
A new publication or filing at PHARMA 9220? We notify you, reason included.
Follow PHARMA 9220Databakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of K & G comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PHARMA 9220Behind PHARMA 9220 is K & G BV. The shares are held by K & G (100%).
Establishments
Establishment units
Physical locations of this company
Hoogstraat 1
9220 Hamme (Vl.)
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1019.772.381
- VAT number
- BE 1019.772.381
- Registered office
- Hoogstraat 1, 9220 Hamme (Vl.)
- Names & denominations
- PHARMA 9220
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 9 February 2025
- Peppol
- Active · Active since 7 Jan 2026
- Activities · NACE
Detailhandel in farmaceutische producten